Immunogenicity and safety of NVSI-06-07

Immunogenicity and safety of NVSI-06-07 by Dr. Nawal AlKaabi

The epidemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has stimulated global efforts to develop safe and effective vaccines against the rapid spread of the virus.

So far, great progress has been achieved, and a total of ten vaccines have been approved by the world health organization (WHO) for emergency use, including three inactivated, two mRNA-based, three viral vector-based and two recombinant nanoparticle protein-based vaccines.

    Fill in your details to download the Whitepaper